Abstract
Purpose: We investigated the antitumor activity of interleukin-12 (IL- 12) against MBT-2, a murine bladder carcinoma, to clarify whether or not IL- 12 is effective against urothelial tumors. Materials and Methods: MBT-2, a murine carcinogen-induced, poorly differentiated transitional cell carcinoma of C3H/He origin, was used. Three or 10 days after the subcutaneous administration of MBT-2 cells, C3H/He mice were injected intraperitoneally with IL-12 five times per wk. for 2 wk. Tumor growth was measured twice weekly. Spleen cells from the C3H/He mice that had rejected MBT-2 after the IL-12 treatment were examined for MBT-2-specific cytolytic T lymphocytes (CTL) activity and cytokine production. Results: Tumor growth and acceptance was obviously suppressed when C3H/He mice were treated with IL-12 from 3 days after the tumor inoculation. In the spleen cells from the C3H/He mice that had rejected MBT-2, MBT-2-specific CTL activity and secretion of IL-2 and interferon (IFN)-γ were clearly detected. However, the established MBT-2 tumor cells were not rejected when C3H/He mice were given IL-12 from 10 days after the tumor inoculation, although the tumor growth was transiently suppressed during the IL-12 treatment. Conclusion: These data demonstrate that IL-12 is considerably effective against murine bladder cancer and suggest the clinical application of IL-12 against human bladder cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 1549-1552 |
| Number of pages | 4 |
| Journal | Journal of Urology |
| Volume | 163 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Jan 1 2000 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Urology
Cite this
Antitumor activity of interleukin-12 against murine bladder cancer. / Eto, Masatoshi; Harada, Mamoru; Tamada, Koji; Tokuda, Noriaki; Koikawa, Yasuhiro; Nakamura, Motonobu; Nomoto, Kikuo; Naito, Seiji.
In: Journal of Urology, Vol. 163, No. 5, 01.01.2000, p. 1549-1552.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antitumor activity of interleukin-12 against murine bladder cancer
AU - Eto, Masatoshi
AU - Harada, Mamoru
AU - Tamada, Koji
AU - Tokuda, Noriaki
AU - Koikawa, Yasuhiro
AU - Nakamura, Motonobu
AU - Nomoto, Kikuo
AU - Naito, Seiji
PY - 2000/1/1
Y1 - 2000/1/1
N2 - Purpose: We investigated the antitumor activity of interleukin-12 (IL- 12) against MBT-2, a murine bladder carcinoma, to clarify whether or not IL- 12 is effective against urothelial tumors. Materials and Methods: MBT-2, a murine carcinogen-induced, poorly differentiated transitional cell carcinoma of C3H/He origin, was used. Three or 10 days after the subcutaneous administration of MBT-2 cells, C3H/He mice were injected intraperitoneally with IL-12 five times per wk. for 2 wk. Tumor growth was measured twice weekly. Spleen cells from the C3H/He mice that had rejected MBT-2 after the IL-12 treatment were examined for MBT-2-specific cytolytic T lymphocytes (CTL) activity and cytokine production. Results: Tumor growth and acceptance was obviously suppressed when C3H/He mice were treated with IL-12 from 3 days after the tumor inoculation. In the spleen cells from the C3H/He mice that had rejected MBT-2, MBT-2-specific CTL activity and secretion of IL-2 and interferon (IFN)-γ were clearly detected. However, the established MBT-2 tumor cells were not rejected when C3H/He mice were given IL-12 from 10 days after the tumor inoculation, although the tumor growth was transiently suppressed during the IL-12 treatment. Conclusion: These data demonstrate that IL-12 is considerably effective against murine bladder cancer and suggest the clinical application of IL-12 against human bladder cancer.
AB - Purpose: We investigated the antitumor activity of interleukin-12 (IL- 12) against MBT-2, a murine bladder carcinoma, to clarify whether or not IL- 12 is effective against urothelial tumors. Materials and Methods: MBT-2, a murine carcinogen-induced, poorly differentiated transitional cell carcinoma of C3H/He origin, was used. Three or 10 days after the subcutaneous administration of MBT-2 cells, C3H/He mice were injected intraperitoneally with IL-12 five times per wk. for 2 wk. Tumor growth was measured twice weekly. Spleen cells from the C3H/He mice that had rejected MBT-2 after the IL-12 treatment were examined for MBT-2-specific cytolytic T lymphocytes (CTL) activity and cytokine production. Results: Tumor growth and acceptance was obviously suppressed when C3H/He mice were treated with IL-12 from 3 days after the tumor inoculation. In the spleen cells from the C3H/He mice that had rejected MBT-2, MBT-2-specific CTL activity and secretion of IL-2 and interferon (IFN)-γ were clearly detected. However, the established MBT-2 tumor cells were not rejected when C3H/He mice were given IL-12 from 10 days after the tumor inoculation, although the tumor growth was transiently suppressed during the IL-12 treatment. Conclusion: These data demonstrate that IL-12 is considerably effective against murine bladder cancer and suggest the clinical application of IL-12 against human bladder cancer.
UR - http://www.scopus.com/inward/record.url?scp=0034051006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034051006&partnerID=8YFLogxK
U2 - 10.1016/S0022-5347(05)67677-X
DO - 10.1016/S0022-5347(05)67677-X
M3 - Article
C2 - 10751886
AN - SCOPUS:0034051006
VL - 163
SP - 1549
EP - 1552
JO - Journal of Urology
JF - Journal of Urology
SN - 0022-5347
IS - 5
ER -